EUROAPI

Company Profile
EUROAPI

We work passionately to develop, manufacture, and supply active ingredient solutions for our healthcare partners around the world. 
We leverage our industrial expertise and experience to deliver solutions that meet the highest quality, social and environmental requirements — all while ensuring stakeholder' satisfaction.

With approximately €1 billion in expected sales by 2022, EUROAPI will rank #1 in small molecule APIs, and our strong innovation and R&D capabilities allow us to accelerate our development in more complex molecules’ segments through CDMO.

Counting approximately 200 APIs, EUROAPI offers one of the largest portfolios in the industry, addressing a wide population of patients and providing global coverage for more than 80 countries. 

Our strategy is a three-pronged, accelerate-expand-develop approach.  

  1. Accelerate our activities as a Contract Development & Manufacturing Organization, through our dedicated team, our six on-site R&D centers of excellence and our 6 top tier manufacturing sites with launching units.
  2. Expand our technological platforms and our presence in highly differentiated complex APIs, with a special focus on Tides and highly potent APIs.
  3. Develop our existing product portfolio through innovative line extension, customer insights on major pharmaceuticals markets and manufacturing capabilities to flourish projects.

At EUROAPI, we’re reinventing active ingredient solutions to sustainably meet customers and patients’ needs around the world.  
Building on Sanofi’s legacy of excellence in ESG, we’re creating a custom, research-backed strategy that addresses the full spectrum of challenges and opportunities available to us, taking into consideration our geographical footprint, our core business, as well as the needs and wellbeing of our employees. 

Building a differentiating ESG strategy requires diverse input. So, we opened a dialogue with more than 1,200 internal and external stakeholders through a survey spanning 30 countries.


Employees, customers, suppliers, investors, non-profits, and more were called upon to share what they expect from an innovative, sustainable industry leader. Their insight was invaluable and gave us a well-rounded base for shaping what would become our key commitments.

The findings of our global survey helped to define our ESG priorities. The resounding takeaway was that expectations are at an all-time high, and we look forward to rising to this occasion.
We’ve identified a range of priorities, which align to three axes:

  1. Create sustainable conditions and ways of working for operational excellence
  2. Work with our partners to ensure compliance and fair practices
  3. Propose innovative processes and services that are sustainable by design
more >

Year of Establishment: 2021

Total Assets(USD):

Total Number of Staff: less than 10 person

Main Competitive Advantages: Brand Name,Reputation,Quality Service

Other Competitive Advantages:

Patents and Copyrights:

Send your message to this supplier
  • From:
  • To:
    EUROAPI
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service